1940s~
The world’s first company to successfully
produce chondroitin sulfate on a commercial scale.

1947

 

Kosei Suisan K.K. established in Minato-ku, Tokyo. 

Kurihama Plant opens in Kanagawa.

1950

 

Industrial production of chondroitin sulfate as a pharmaceutical begins. 

1952

 

Head Office relocated to Chuo-ku, Tokyo.

1953

 

Name of company changed to K.K. Seikagaku Kenkyusho. 

1960

 

Tokyo Research Institute opens in Shinjuku-ku, Tokyo. 

Development and marketing of research biochemicals begins. 

1962

 

Name of company changed to Seikagaku Corporation. 

1968

 

Tokyo Research Institute relocated to Higashiyamato-shi, Tokyo. 

1970s~
Pharmaceuticals using hyaluronic acid are developed.

1975

 

Takahagi Plant opens in Ibaraki. 

1981

 

World's first endotoxin colorimetry reagent developed and manufactured. 

1987

 

Marketing begins for hyaluronic acid formulations ARTZ and OPEGAN. 

1989

 

Company stock registered with the Japan Securities Dealers Association (Now JASDAQ). 

1990s~
Enhances its range of pharmaceuticals using hyaluronic acid
and expands its activities in overseas markets.

1992

 

Overseas marketing of ARTZ begins (Sweden). 

1993

 

Marketing begins for ARTZ Dispo, a new formulation. 

1997

 

Acquisition of Associates of Cape Cod, Inc. (U.S.A.) 

1998

 

Quality Management System certification ISO 9001/EN 46001, ISO 13485 obtained (superseded by ISO 13485 certification since 2010). 

2000

 

Name of Tokyo Research Institute changed to Central Research Laboratory. 

2001

 

Marketing begins for hyaluronic acid formulation SUPARTZ in U.S.A. 

2004

 

Listing moved to the Tokyo Stock Exchange, Second Section. 

2005

 

Listing moved to the Tokyo Stock Exchange, First Section. 

Head Office relocated to Chiyoda-ku, Tokyo. 

2007

 

Marketing begins for a hyaluronic acid medical device MucoUp. 

Seikagaku Biobusiness Corporation established. 

2012

 

Marketing begins for a single injection hyaluronic acid formulation Gel-One in U.S.A. 

Absorption-type Merger of Seikagaku Biobusiness Corporation. 

2013

 

CMC Laboratory established. 

2016

 

Marketing begins for SHELLGAN 0.5 Ophthalmic viscoelastic devices for the ophthalmic surgcal aid in Japan. 

2018~
Reaches a new stage with the launch of a treatment agent
for lumbar disc herniation.

2018

 

Marketing begins for HERNICORE 1.25 Units for Intradiscal Injection in Japan. 

2019

 

Marketing begins for HyLink Intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy.